LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Tyrosine kinase inhibitor-induced immune hemolytic anemia; three different drugs in three separate cases.

    Güzel, Halil Göksel / Kıvrak Salim, Derya

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

    2023  Volume 30, Issue 1, Page(s) 215–219

    Abstract: Introduction: Molecular multitargeted small tyrosine kinase inhibitory (TKI) agents such as axitinib, sunitinib and pazopanib are commonly used in several types of solid tumors. Anemia is not a rare effect of these drugs which may occur at all grades. ... ...

    Abstract Introduction: Molecular multitargeted small tyrosine kinase inhibitory (TKI) agents such as axitinib, sunitinib and pazopanib are commonly used in several types of solid tumors. Anemia is not a rare effect of these drugs which may occur at all grades. However, drug-induced immune hemolytic anemia (IHA), a very rare condition is distinctive from other types of anemia with its specific mechanism and management strategy.
    Case reports: We reported three different TKI-induced IHA cases that occurred due to axitinib, sunitinib, and pazopanib, respectively. The first two cases were diagnosed with renal cell carcinoma and the last one was diagnosed with soft tissue sarcoma. They all presented with the characteristic symptoms of anemia and hemolysis. All the cases were detected positive for the complement C3d direct antiglobulin (direct coombs) test.
    Management and outcomes: Discontinuation of the causative drug and 1 mg/kg/day dose of corticosteroid treatment were able to control IHA in all three cases. Excluding the other factors of IHA and an evident laboratory and clinical benefit after withholding the TKI led to the diagnosis of TKI-related IHA in each case.
    Discussion: TKIs are relatively new in clinical practice and are being used for more indications and in more patients. To our knowledge#these three cases are unique in terms of axitinib#sunitinib#and pazopanib-related IHA.
    MeSH term(s) Humans ; Anemia, Hemolytic/chemically induced ; Anemia, Hemolytic/drug therapy ; Axitinib/therapeutic use ; Carcinoma, Renal Cell/drug therapy ; Indazoles ; Protein Kinase Inhibitors/adverse effects ; Pyrimidines ; Sulfonamides ; Sunitinib/adverse effects ; Tyrosine Kinase Inhibitors
    Chemical Substances Axitinib (C9LVQ0YUXG) ; Indazoles ; pazopanib (7RN5DR86CK) ; Protein Kinase Inhibitors ; Pyrimidines ; Sulfonamides ; Sunitinib (V99T50803M) ; Tyrosine Kinase Inhibitors
    Language English
    Publishing date 2023-09-19
    Publishing country England
    Document type Journal Article
    ZDB-ID 1330764-2
    ISSN 1477-092X ; 1078-1552
    ISSN (online) 1477-092X
    ISSN 1078-1552
    DOI 10.1177/10781552231202530
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4488: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Rapidly developing facial and intertriginous hyperpigmentation with acral erythema after docetaxel infusion.

    Eryılmaz, Melek Karakurt / Tazegul, Gokhan / Ünal, Betül / Müsri, Fatma Yalçin / Güzel, Halil Göksel / Coşkun, Hasan Şenol

    Journal of cancer research and therapeutics

    2021  Volume 17, Issue 1, Page(s) 293–294

    MeSH term(s) Adenocarcinoma of Lung/drug therapy ; Antineoplastic Agents/adverse effects ; Docetaxel/adverse effects ; Face ; Facial Dermatoses/chemically induced ; Facial Dermatoses/diagnosis ; Facial Dermatoses/pathology ; Hand-Foot Syndrome/diagnosis ; Hand-Foot Syndrome/etiology ; Hand-Foot Syndrome/pathology ; Humans ; Hyperpigmentation/chemically induced ; Hyperpigmentation/diagnosis ; Hyperpigmentation/pathology ; Lung Neoplasms/drug therapy ; Male ; Middle Aged
    Chemical Substances Antineoplastic Agents ; Docetaxel (15H5577CQD)
    Language English
    Publishing date 2021-03-15
    Publishing country India
    Document type Case Reports ; Letter
    ZDB-ID 2187633-2
    ISSN 1998-4138 ; 0973-1482
    ISSN (online) 1998-4138
    ISSN 0973-1482
    DOI 10.4103/jcrt.JCRT_385_17
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Regulatory B Cells Profile in Kidney Transplant Recipients With Chronic-Active Antibody-Mediated Rejection.

    Guzel, Halil Goksel / Yilmaz, Vural Taner / Koksoy, Sadi / Kocak, Huseyin / Kisaoglu, Abdullah / Soylu, Mehmet / Akkaya, Bahar / Demiryilmaz, Ismail / Aydinli, Bülent / Suleymanlar, Gultekin

    Transplantation proceedings

    2023  Volume 55, Issue 5, Page(s) 1140–1146

    Abstract: This study aims to reveal the relationship between regulatory B cell (Breg) subsets and chronic-active antibody-mediated rejection (c-aABMR) in renal transplant recipients. Our study involved 3 groups of participants: renal transplant recipients with ... ...

    Abstract This study aims to reveal the relationship between regulatory B cell (Breg) subsets and chronic-active antibody-mediated rejection (c-aABMR) in renal transplant recipients. Our study involved 3 groups of participants: renal transplant recipients with biopsy-proven c-aABMR as the chronic rejection group (c-aABMR, n = 23), recipients with stable graft functions as the patient control group (PC; n = 11), and healthy volunteers (HV; n = 11). Breg subsets, immature/transitional B cells, plasmablastic cells, B10 cells, and BR1 cells were isolated from venous blood samples by flow cytometry. The median values of Breg frequencies in the total lymphocyte population were analyzed. There were no significant differences between the study groups for immature and/or transitional B cell frequencies. Plasmablastic cell frequencies of the c-aABMR group (7.80 [2.10-27.40]) and the PC group (6.00 [1.80-55.50]) were similar, but both of these values were significantly higher than the HVs' (3.40 [1.20-8.50]), (respectively, P = .005 and P = .039). B10 cell frequencies were also similar, comparing the c-aABMR (4.20 [0.10-7.40]) and the PC groups (4.10 [0.10-5.90]), whereas the HVs (5.90 [2.90-8.50]) had the highest B10 cell frequency with an only statistical significance against the PC group (respectively, P = .09 and P = .028). The c-aABMR and the PC groups were similar regarding BR1 cell frequencies. However, the HV group significantly had the highest frequency of BR1 cells (5.50 [2.80-10.80]) than the other groups (P < .001 for both). We demonstrated that frequencies of B10 and BR1 cells were higher in HVs than in transplant recipients, regardless of rejection state. However, there was no significant relation between Breg frequencies and the c-aABMR state.
    MeSH term(s) Humans ; Kidney Transplantation/adverse effects ; B-Lymphocytes, Regulatory ; Transplant Recipients ; Antibodies ; Kidney ; Graft Rejection
    Chemical Substances Antibodies
    Language English
    Publishing date 2023-04-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 82046-5
    ISSN 1873-2623 ; 0041-1345
    ISSN (online) 1873-2623
    ISSN 0041-1345
    DOI 10.1016/j.transproceed.2023.03.029
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 835: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study.

    Yildirim, Hasan Cagri / Kapar, Caner / Koksal, Baris / Seyyar, Mustafa / Sanci, Pervin Can / Guliyev, Murad / Perkin, Perihan / Buyukkor, Mustafa / Yaslikaya, Sendag / Majidova, Nargiz / Keskinkilic, Merve / Ozaskin, Duygu / Avci, Tugay / Gunes, Tugce Kubra / Arcagok, Murat / Topal, Alper / Keskin, Gul Sema Yildiran / Kavgaci, Gozde / Yildirim, Nilgun /
    Celayir, Ozde Melisa / Avci, Nilufer / Aslan, Ferit / Alkan, Ali / Erciyestepe, Mert / Cengiz, Muhammet / Pehlivan, Metin / Gulmez, Ahmet / Beypinar, Ismail / Basoglu Tuylu, Tugba / Kayikcioglu, Erkan / Chalabiyev, Elvin / Turhal, Serdal / Guzel, Halil Goksel / Ayas, Eyyup / Sahbazlar, Mustafa / Dulgar, Ozgecan / Demir, Hacer / Yavuzsen, Tugba / Bayoglu, Vedat / Kivrak Salim, Derya / Ozturk, Banu / Ozdemir, Feyyaz / Kara, Oguz / Oksuzoglu, Berna / Bal, Oznur / Demirci, Nebi Serkan / Yilmaz, Mesut / Cabuk, Devrim / Aksoy, Sercan

    Journal of chemotherapy (Florence, Italy)

    2024  , Page(s) 1–7

    Abstract: The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment in premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is the MONALEESA-7 study, and data on the effectiveness of ... ...

    Abstract The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment in premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is the MONALEESA-7 study, and data on the effectiveness of palbociclib is limited. Data are also limited regarding the effectiveness of CDK 4-6 inhibitors in patients whose dose was reduced due to neutropenia, the most common side effect of CDK 4-6 inhibitors. In our study, we aimed to evaluate the effectiveness of palbociclib and ribociclib in first-line treatment in patients with premenopausal metastatic breast cancer and the effect of dose reduction due to neutropenia on progression-free survival. Our study is a multicenter, retrospective study, and factors affecting progression-free survival (PFS) were examined in patients diagnosed with metastatic premenopausal breast cancer from 29 different centers and receiving combination therapy containing palbociclib or ribociclib in the metastatic stage. 319 patients were included in the study. The mPFS for patients treated with palbociclib was 26.83 months, and for those receiving ribociclib, the mPFS was 29.86 months (
    Language English
    Publishing date 2024-03-18
    Publishing country England
    Document type Journal Article
    ZDB-ID 1036294-0
    ISSN 1973-9478 ; 1120-009X
    ISSN (online) 1973-9478
    ISSN 1120-009X
    DOI 10.1080/1120009X.2024.2330835
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2701: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 387: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.

    Ünal, Çağlar / Azizy, Abdulmunir / Karabulut, Senem / Taştekin, Didem / Akyıldız, Arif / Yaşar, Serkan / Yalçın, Şuayib / Çoban, Eyüp / Evrensel, Türkkan / Kalkan, Ziya / Oruç, Zeynep / Derin, Sümeyra / Turna, Zeynep Hande / Bayram, Doğan / Köş, Fahriye Tuğba / Şendur, Mehmet Ali Nihat / Sever, Nadiye / Ercelep, Özlem / Seyyar, Mustafa /
    Kefeli, Umut / Uygun, Kazım / Özçelik, Melike / Ön, Sercan / Şanlı, Ulus Ali / Canaslan, Kübra / Ünek, İlkay Tuba / Yücel, Kadriye Bir / Özdemir, Nuriye / Yazıcı, Ozan / Güzel, Halil Göksel / Salim, Derya Kıvrak / Göksu, Sema Sezgin / Tatlı, Ali Murat / Ordu, Çetin / Selvi, Oğuzhan / Sakin, Abdullah / Büyükbayram, Mehmet Emin / Dursun, Bengü / Ürün, Yüksel / Arak, Hacı / Ağdaş, Gözde / Uğraklı, Muzaffer / Hendem, Engin / Eryılmaz, Melek Karakurt / Bilgin, Burak / Topçu, Atakan / Şimşek, Melih / Büyükşimşek, Mahmut / Akay, Büşra / Erdal, Gülçin Şahingöz / Karataş, Fatih / Alan, Özkan / Çağlayan, Melek / Kahvecioğlu, Fatma Akdağ / Demirci, Ayşe / Paksoy, Nail / Çetin, Bülent / Gümüş, Mahmut / Ak, Naziye / Aydınalp, Yasemin / Paydaş, Semra / Güven, Deniz Can / Kılıçkap, Saadettin / Sağlam, Sezer

    The oncologist

    2023  Volume 28, Issue 10, Page(s) 875–884

    Abstract: Introduction: This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs).: Methods: We conducted a multicenter ... ...

    Abstract Introduction: This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs).
    Methods: We conducted a multicenter retrospective study analyzing the data of 308 patients with metastatic NETs treated with CAPTEM between 2010 and 2022 in 34 different hospitals across various regions of Turkey.
    Results: The median follow-up time was 41.0 months (range: 1.7-212.1), and the median age was 53 years (range: 22-79). Our results across the entire patient cohort showed a median progression-free survival (PFS) of 10.6 months and a median overall survival (OS) of 60.4 months. First-line CAPTEM treatment appeared more effective, with a median PFS of 16.1 months and a median OS of 105.8 months (median PFS 16.1, 7.9, and 9.6 months in first-, second- and ≥third-line respectively, P = .01; with median OS values of 105.8, 47.2, and 24.1 months, respectively, P = .003) In terms of ORR, the first-line treatment again performed better, resulting in an ORR of 54.7% compared to 33.3% and 30.0% in the second and third or higher lines, respectively (P < .001). Grade 3-4 side effects occurred only in 22.5% of the patients, leading to a discontinuation rate of 9.5%. Despite the differences in outcomes based on treatment line, we did not observe a significant difference in terms of side effects between the first and subsequent lines of treatment.
    Conclusions and relevance: The substantial superior outcomes in patients receiving first-line CAPTEM treatment highlight its potential as an effective treatment strategy for patients with metastatic NET.
    MeSH term(s) Humans ; Middle Aged ; Capecitabine/adverse effects ; Temozolomide/therapeutic use ; Neuroendocrine Tumors/drug therapy ; Neuroendocrine Tumors/pathology ; Retrospective Studies ; Turkey/epidemiology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Treatment Outcome
    Chemical Substances Capecitabine (6804DJ8Z9U) ; Temozolomide (YF1K15M17Y)
    Language English
    Publishing date 2023-09-07
    Publishing country England
    Document type Multicenter Study ; Journal Article
    ZDB-ID 1409038-7
    ISSN 1549-490X ; 1083-7159
    ISSN (online) 1549-490X
    ISSN 1083-7159
    DOI 10.1093/oncolo/oyad257
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4845: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 494: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top